Kiromic BioPharma, Inc. (null) aktie

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.